|Bid||1,130.00 x 16300|
|Ask||1,290.00 x 34600|
|Day's Range||1,133.00 - 1,190.00|
|52 Week Range||1,101.00 - 2,346.00|
|PE Ratio (TTM)||16.45|
|Earnings Date||Mar 14, 2017 - Mar 20, 2017|
|Dividend & Yield||0.22 (1.44%)|
|1y Target Est||18.06|
MADISON, Wis., Sept. 19, 2017 /PRNewswire/ -- Today, Propeller Health released the results from three new asthma and COPD studies presented last week at the European Respiratory Society International Congress (ERS) in Milan, Italy. The five-day event is the world's largest respiratory health meeting. The company shared interim results on the feasibility and clinical impact of a digital health intervention (Propeller) among a Medicare population with COPD.
Stocks with market capitalization between $2B and $10B, such as Hikma Pharmaceuticals PLC (LSE:HIK) with a size of £2.89B, do not attract as much attention from the investing community asRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hikma Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to HIK-GB. Comparing the performance and risk of Hikma Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)